In 2022, the total market size of anti-adhesion products in Korea is estimated to be approximately ***USD (manufacturers/importers' initial selling prices) and ***USD (medical institutions' purchase prices).

Afterwards, it is expected to maintain an average annual growth rate of ***% over the next five years and as a result, the market size is projected to be approximately ***USD (manufacturers/importers' initial selling prices) and ***USD (medical institutions' purchase prices).

It is estiemated that out of around ***USD (medical institutions' purchase prices) in 2022, approximately ***USD was from National Health Insurance reimbursement, and the remaining about ***USD was out-of-pocket costs (non-reimbursement). Currently, all postoperative anti-adhesion products are reimbursed (select reimbursement, out-of-pocket 80%), and only spinal epidural anti-adhesion products are the subject of non-reimbursement claims.

The reimbursement volume for anti-adhesion products in 2022, ***USD is about ***% increase from ***USD in 2021. In 2021 (approximately ***USD), it grew rapidly by about ***% compared to 2020 (approximately ***USD) which can be interpreted as a result of the implementation of the new National Health Insurance reimbursement
system effective from January 2020. It was the first year that postoperative anti-adhesion products on the reimbursement list could be billed for full separate non-inclusive claims
under the 7-DRG system.

Looking at the 2022 reimbursement claims of the anti-adhesion products by medical department, general surgery is about ***USD and obstetrics and gynegology is about ***USD, accounting for about *** of the total claims. The remaining ***% includes orthopedics about ***USD, otolaryngology/internal medicine about ***USD, urology about ***USD, thoracic surgery about ***USD, and neurosurgery about ***USD.

Looking at the 2022 reimbursement claims of the anti-adhesion products by end-user type, tertiary hospitals account for approximately ***USD, the largest portion of the total reimbursement volume (about ***USD). This is followed by general hospitals about ***USD (***%) and hospitals about ***USD (***%). One of the natures of the anti-adhesion products is that they are closely related to surgical operations. Therefore, among various types of medical institutions, the combined claims of tertiary hospitals and general hospitals account for approximately ***% of the total claims.

In 2022, about *** products from *** manufacturers/importers are listed on the National Health Insurance of Korea.
Major suppliers of the anti-adhesion product market include GC Biopharma, Dalim Tissen, Medtronic, Baxter, Samyang Holdings, CG Bio, Shin Poong Pharm, LG Chem, Genewel, BNC Korea, CareRex, BMI Korea and Johnson & Johnson Medtech (in Korean-alphabetical order).

Among them, it is estimated that the combined market share of the top three suppliers accounted for about ***% of the total market, while the remaining 10 suppliers accounted for about ***% of the market. The market share of the top three suppliers is estimated as follows: Genewel (manufacturer of Guardix) about ***%, CG Bio (manufacturer and supplier of Mediclore) about ***% and Shin Poong Pharm (manufacturer and supplier of Medicurtain) about ***%.

The anti-adhesion product market is expected to continue to grow at an average annual rate ot ***% for the next five years driven by the following factors: competition for a bigger number of hospital beds, aging population, increasing numbers of surgeries, laparoscopic procedures, obstetrics and gynegology treatments and surgeris, spinal surgeris, 7-DRG surgeries, and subscribers of indemnity medical insurance, raised awareness of anti-adhesion products and attitude changes of the patients. On the other hand, since the National Health Insurance determines the reimbursement price based on the physical state, size and capacity of the product, it can be a restraint factor to the emergence or supply of anti-adhesion products which attempt and/or utilize various materials and substances.

Chapter 1 Introduction
   1.1 Purpose
   1.2 Suggestion for Best Use
   1.3 Scope
   1.4 Market Segmentation
   1.5 Research Methods
      1.5.1 Desk Research
      1.5.2 Primary Research
   1.6 Analytic and Projection Methods of Market Size
      1.6.1 Data Sources
      1.6.2 Exchange Rate
      1.6.3 Market Size Estimation Methods
         1.6.3.1 Reimbursement Size Estimation Methods

Chapter 2 Executive Summary

Chapter 3 Market Overview
   3.1 Market Size at Manufacturers/Importers' Initial Selling Prices
      3.1.1 Five-Year Forecast of Market Size
   3.2 Market Size at Medical Institutions' Purchase Prices
      3.2.1 Reimbursement Volume of Anti-Adhesion Products
         3.2.1.1 Reimbursement Volume by Medical Department
         3.2.1.2 Reimbursement Volume by End-User Type
      3.2.2 Reimbursement Volume by Physical State of Product
         3.2.2.1 Reimbursement Volume by Physical State of Product & Medical Department
         3.2.2.2 Reimbursement Volume by Physical State of Product Category & End-User Type

Chapter 4 Major Suppliers
   4.1 GC Biopharma
   4.2 Dalim Tissen
   4.3 Medtronic
   4.4 Baxter
   4.5 Samyang Holdings
   4.6 CG Bio
   4.7 Shinpoong Pharm
   4.8 LG chem
   4.9 Genewel
   4.10 BNC Korea
   4.11 CareRex
   4.12 BMI Korea
   4.13 Johnson& Johnson Medical

Chapter 5 Market Dynamics
   5.1 Impact of COVID-19
   5.2 Characteristics of Healthcare Market in Korea
      5.2.1 History of Anti-Adhesion Products
      5.2.2 Change History of Payment Environment
      5.2.3 Number of Medical Institutions in Korea
      5.2.4 Determination Criteria for Reimbursement vs. Non-Reimbursement
   5.3 Key Indicators of Anti-Adhesion Market
      5.3.1 Rising Costs and Competition for More Beds
      5.3.2 Aging Population
      5.3.3 Number of Surgical Operations
      5.3.4 Number of Laparoscopic Procedures
      5.3.5 Obstetrics and Gynecology Treatments and Surgical Operations
      5.3.6 Urology Treatments
      5.3.7 Orthopedic Treatments and Surgical Operations
      5.3.8 Otolaryngology / Internal Medicine Treatments and Surgical Operations
      5.3.9 Seven Diagnosis-Related Groups
   5.4 Market Drivers
      5.4.1 Demand
      5.4.2 Increase in Number of Suppliers
   5.5 Market Opportunities
      5.5.1 Rising Demand with Surgical Operations
      5.5.2 Reimbursement Coverage Expansion Policy
      5.5.3 Reimbursement of Medical Devices as Product Fees in the Seven DRG Payment Scheme
      5.5.4 Clinical Trials on New Anti-Adhesion Technologies
   5.6 Market Restraints
      5.6.1 Reimbursement Pricing Scheme of National Health Insurance
      5.6.2 Concentration of Specific Physical States
   5.7 Unmet Needs

Appendix1 Reimbursement Volume of Postoperative Anti-Adhesion Products (2016-2020)
Appendix2 Major Products Included in This Report for Market Estimation (As of 01 March 2023)
Appendix3 Products for Anti-Adhesion Market Research (As of 01 March 2023)

[Table 1] Classification of Anti-Adhesion Products Approval
[Table 2] Market Size of Initial Selling Price 2018-2022 (in USD)
[Table 3] Five-Year Forecast of Market Size 2022-2026 (in USD)
[Table 4] Reimbursement Volume of Anti-Adhesion Products 2018-2022
[Table 5] Reimbursement Volume by Medical Department 2018-2022
[Table 6] Market Size Forecast for Major Medical Departments
[Table 7] Reimbursement Volume by End-User Type 2018-2022
[Table 8] Reimbursement Volume by Product Category 2018-2022
[Table 9] Reimbursement Volume by Product Category & Medical Department 2021-2022
[Table 10] Reimbursement Volume by Product Category & End-User Type 2021-2022
[Table 11] Manufacturers and Suppliers of Key Brands
[Table 12] Ingredients and Shapes of Key Brands
[Table 13] Characteristics of Each Product Shape
[Table 14] Key Brand of GC Biopharm - Hyalobarrier
[Table 15] Key Brand of Dalim Tissen - Collabarrier
[Table 16] Key Brand of Medtronic - Medishield
[Table 17] Key Brand of Baxter - Adept
[Table 18] Key Brand of Baxter - Sepra Film
[Table 19] Key Brand of Samyang Holdings - Interguard
[Table 20] Key Brand of CG Bio - Mediclore
[Table 21] Key Brand of Shin Poong Pharm - Medicurtain
[Table 22] Key Brand of LG Chem - Protescal
[Table 23] Key Brand of Genewel - Guardix SOL
[Table 24] Key Brand of Genewel - Guardix SG
[Table 25] Key Brand of Genewel - Guardix SP
[Table 26] Key Brand of Genewel - Guardix SP Plus
[Table 27] Key Brand of BNC Korea - Hibarry
[Table 28] Key Brand of CareRex - SurgiWrap
[Table 29] Key Brand of BMI Korea - Qblock
[Table 30] Key Brand of Johnson & Johnson Medtech - Interceed
[Table 31] Number of Medical Institutions (2022)
[Table 32] Number of Beds for Major Hospitals (2022)
[Table 33] Determination Criteria for Reimbursement and Non-Reimbursement
[Table 34] Total Number of Beds for Hospitals of OECD countries (as of 2021)
[Table 35] Estimated Health Spending and GDP of OECD Countries 2021
[Table 36] Estimate of Elderly Population Over 65 Years Old
[Table 37] Healthcare Spending for Elderly Population (over 65 years old)
[Table 38] Number of Surgical Claims 2017-2021
[Table 39] Trend in Number of Surgical Operations (2017-2021)
[Table 40] Number of Laparoscopic Surgeries (2017-2021)
[Table 41] Obstetrics and Gynecology Care (2017-2021)
[Table 42] Obstetrics and Gynecology Surgical Operations (DRG Cases) (2017-2021)
[Table 43] Obstetrics and Gynecology Surgical Operations (2017-2021)
[Table 44] Urology Care (2017-2021)
[Table 45] Orthopedic Care (2017-2021)
[Table 46] Trend in Number of Spinal Surgical Operations (2017-2021)
[Table 47] Otolaryngology and Internal Medicine Care (2017-2021)
[Table 48] Thyroid Surgery Operations (2017-2021)
[Table 49] DRG Claim Cases (2017-2021)
[Table 50] Summary of Market Drivers
[Table 51] Changes in Number of Anti-Adhesion Products
[Table 52] Clinical Trials of Anti-Adhesion Products 2018-2022 (as of 1 March 2023)
[Table 53] Classification Method and Reimbursement Criteria for Anti-Adhesion Products
(as of 1 March 2021)
[Table 54] Non-Reimbursement Price Comparison for Spinal-Epidural Anti-Adhesion Products
(as of March 2023, in KRW)

[Fig 1] Market Size of Initial Selling Prices 2018-2022 (in USD)
[Fig 2] Five-Year Forecast of Market Size 2022-2026 (in USD)
[Fig 3] Market Size at Hospital Acquisition Price (2022)
[Fig 4] Market Size Forecast at Hospital Acquisition Price (2027)
[Fig 5] Reimbursement Volume of Anti-Adhesion Products (2018-2022)
[Fig 6] Reimbursement Volume by Medical Department 2022 (in USD)
[Fig 7] Trend in Reimbursement Volume by Medical Department 2018-2022
[Fig 8] Reimbursement Volume by End-User Type 2022 (in USD)
[Fig 9] Reimbursement Volume by End-User Type 2018-2022
[Fig 10] Reimbursement Volume by Product Category 2022 (in USD)
[Fig 11] Reimbursement Volume by Product Category 2018-2022
[Fig 12] Reimbursement Volume by Product Category and Medical Department 2022 (in USD)
[Fig 13] Reimbursement Volume by Product Category and Medical Department 2022 (in USD)
[Fig 14] Reimbursement Volume by Product Category and End-User Type 2022 (in USD)
[Fig 15] Reimbursement Volume by Product Category and End-User Type 2022 (Unit: number of claim cases)
[Fig 16] Estimated Market Share of Key Anti-Adhesion Products 2022
[Fig 17] Trend in Number of COVID-19 Patients 2020-2022
[Fig 18] Reimbursement Claim Volume of Big 5 Hospitals 2016-2020 (in USD)
[Fig 19] Ranking of Tertiary Hospitals with Decreased Reimbursement Volume (2018-2021 Q3)
[Fig 20] Number of Medical Institutions (2012-2021)
[Fig 21] Trend in Healthcare Spending Compared to GDP (2012-2021)
[Fig 22] Percentage of Elderly Population (65 years+)
[Fig 23] Health Spending on Elderly Population: 65 years+ (in USD per 1,000 persons)
[Fig 24] Number of Surgical Operations (2018-2022)
[Fig 25] Number of Laparoscopy Care Patients 2017-2021
[Fig 26] Number of Obstetrics and Gynaecology Treatments 2017-2021 (Unit: 1,000 cases)
[Fig 27] Number of Urology Treatments 2017-2021 (Unit: 1,000 cases)
[Fig 28] Number of Orthopedic Treatments 2017-2021 (Unit: 1,000 cases)
[Fig 29] Number of Spinal Surgical Operations 2017-2021
[Fig 30] Number of Otolaryngology and Internal Medicine Treatments 2017-2021 (Unit: 1,000 cases)

1 GC Biopharma
2 Dalim Tissen
3 Medtronic
4 Baxter
5 Samyang Holdings
6 CG Bio
7 Shinpoong Pharm
8 LG chem
9 Genewel
10 BNC Korea
11 CareRex
12 BMI Korea
13 Johnson&Johnson Medical